

10-01-02

1614

#13

Express Mail Label No.: EV 019 435 843 US

Date of Deposit: September 30, 2002

Attorney Docket No. VPI/99-06 CON US



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Francesco G. Salituro et al.  
 ASSIGNEE: Vertex Pharmaceuticals Incorporated  
 SERIAL NUMBER: 10/008,277 EXAMINER: Not Yet Assigned  
 FILING DATE: December 3, 2001 ART UNIT: 1614  
 FOR: INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)

September 30, 2002  
 Cambridge, Massachusetts

Commissioner for Patents  
 Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the National Application;
- within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

RECEIVED  
 OCT 02 2002  
 TECH CENTER 1600/2900

TECH CENTER 1600/2900

RECEIVED  
 OCT 17 2002

APPLICANTS: Salituro  
U.S.S.N.: 10/008,277

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/99-06 CON US.

Respectfully submitted,

*Karoline K. M. Shair*  
\_\_\_\_\_  
Karoline Shair and Reg. No. 44,332  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6536  
Fax: (617) 444-6483

RECEIVED

OCT 02 2002


Express Mail No. EV 019 435 843 US

OCT 17 2002

Date of Deposit: September 30, 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900



Modified Form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/008,277
	Filing Date	December 3, 2001
	First Named Inventor	Francesco G. Salituro
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/99-06 CON US

## U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
A1		4,920,126	24-Apr-1990	Uniroyal Chemical Ltd/Uniroyal Chemical Ltee			

## FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
B1		WO 99/64400	Vertex Pharmaceuticals Incorporated	16-Dec-1999	
B2		WO 00/75118	Vertex Pharmaceuticals Incorporated	14-Dec-2000	
B3		WO 99/58502	Vertex Pharmaceuticals Incorporated	18-Nov-1999	

## OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C1		Tominaga, Y., et al., "Synthesis of Pyrimidine Derivatives Using N-bis(methylthio)methylenecyanamide", retrieved from STN Database accession no. 115:183231, XP002147665, RNs 136411-38-6, 136411-49-9 and markers & <i>J. Heterocycl. Chem.</i> , 28(4):1039-1042 (1991).
C2		Supko, J. G., et al., "Concurrent Determination of Merbarone and its Urinary Metabolites by Reversed-Phase HPLC with Precolumn Phenolic Acetylation", retrieved from STN Database accession no. 115:173977, XP002147666 RM 136527-39-4 and <i>J. Liq. Chromatogr.</i> , 14(11):2169-2188 (1991).
C3		Bell, L., et al., "Chemistry of 5-pyrimidinecarboxaldehydes", retrieved from STN Database accession no. 99:22414, XP002147667, RN 85840-29-5 and marker & <i>J. Heterocycl. Chem.</i> , 20(1):41-44 (1983).
C4		Lamon, R.W., et al., "Thermal Rearrangement of 6-ethoxy-4-thiouracils and related compounds O, S-alkyl migration in the pyrimidine series", retrieved from STN Database accession no. 74:3582, XP002147668, RN 30001-43-5 and marker & <i>Tetrahedron Lett.</i> , (45):3957-3960 (1970).
C5		Database Cas Registry 'Online', XP002147669, RN 264884-33-5 and marker.
C6		Database Cas Registry 'Online', XP002147670, RN 7357-33-7 and marker.
C7		Iordanov, M.S., et al., "Ribotoxic stress response: Activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the $\alpha$ -sarcin/ricin loop in the 28S rRNA", retrieved from STN Database accession no. 127:79177, XP002147671, abstract and <i>Mol. Cell. Biol.</i> , 17(6):3373-3381 (1997).
C8		Allison, A.C., "Immunosuppressive drugs: the first 50 years and a glance forward", retrieved from STN Database accession no. 2000420734 Medline, XP002147672, abstract and <i>Immunopharmacology</i> , 47(2-3):63-83 (2000).
C9		Tominaga, Y., et al., "Synthesis of Pyrimidine Derivatives Using N-bis(methylthio)methylenecyanamide", <i>J. Heterocycl. Chem.</i> , 28(4):1039-1042 (1991).
C10		Bell, L., et al., "Chemistry of 5-Pyrimidinecarboxaldehydes", <i>J. Heterocycl. Chem.</i> , 20(1):41-44 (1983).
C11		Lamon, R.W., "The Thermal Rearrangement of 6-Ethoxy-4-Thiouracils and Related Compounds. An O, S-Alkyl Migration in the Pyrimidine Series", <i>Tetrahedron Letters</i> , (45):3957-3960 (1970).
C12		Allison, A.C., "Immunosuppression drugs: the first 50 years and a glance forward", <i>Immunopharmacology</i> , 47:63-83 (2000).
C13		Wang, Z., et al., "Structural basis of inhibitor selectivity in MAP kinases", <i>Structure</i> , 6(9):1117-1128 (1998).
C14		Iordanov, M.S., et al., Ribotoxic Stress Response: Activation of the Stress-Activated Protein Kinase JNK1 by Inhibitors of the Peptidyl Transferase Reaction and by Sequence-Specific RNA Damage to the $\alpha$ -Sarcin/Ricin Loop in the 28S rRNA", <i>Mol. Cell. Biol.</i> , 17(6):3373-3381 (1997).



#### **OTHER NON PATENT LITERATURE DOCUMENTS**

~~RECEIVED~~

OCT 02 2002

TECH CENTER 1600/2900

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TBAROCS:1161763.16 (WE7011.ROC)

RECEIVED  
OCT 17 2002  
TECH CENTER 1600/2900